South San Francisco drug developer Spitfire Pharma to be acquired by Maryland biotech
The deal puts Spitfire’s flagship product candidate — a treatment for non-alcoholic steatohepatitis, or NASH — into Altimmune’s pipeline of flu and anthrax vaccines.